Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBIT Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBIT Margin for 16 consecutive years, with 70.53% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 5120.0% to 70.53% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 69.95% through Dec 2025, down 4950.0% year-over-year, with the annual reading at 69.95% for FY2025, 4950.0% down from the prior year.
  • EBIT Margin hit 70.53% in Q4 2025 for Vanda Pharmaceuticals, down from 55.61% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 18.22% in Q2 2021 to a low of 81.99% in Q1 2025.
  • Historically, EBIT Margin has averaged 16.28% across 5 years, with a median of 14.09% in 2023.
  • Biggest five-year swings in EBIT Margin: skyrocketed 1672bps in 2021 and later tumbled -6253bps in 2025.
  • Year by year, EBIT Margin stood at 12.7% in 2021, then fell by -19bps to 10.28% in 2022, then tumbled by -252bps to 15.67% in 2023, then dropped by -23bps to 19.33% in 2024, then crashed by -265bps to 70.53% in 2025.
  • Business Quant data shows EBIT Margin for VNDA at 70.53% in Q4 2025, 55.61% in Q3 2025, and 73.21% in Q2 2025.